Nehmi Filho, Victor; Santamarina, Aline Boveto; Freitas, Jéssica Alves de; Trarbach, Ericka Barbosa; Oliveira, Daniela Rodrigues de; Palace-Berl, Fanny; Souza, Erica de; Miranda, Danielle Araujo de; Garcia, Antônio Escamilla; Otoch, José Pinhata 
; Pessoa, Ana Flávia Marçal
Fonte: Frontiers in Endocrinology. Unidade: HU
Assuntos: SUPLEMENTOS DIETÉTICOS, PREBIÓTICOS, OBESIDADE, ENDOCRINOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NEHMI FILHO, Victor et al. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial. Frontiers in Endocrinology, v. 13, n. ja 2023, p. 1089938, 2023Tradução . . Disponível em: https://doi.org/10.3389/fendo.2022.1089938. Acesso em: 10 maio 2024.APA
Nehmi Filho, V., Santamarina, A. B., Freitas, J. A. de, Trarbach, E. B., Oliveira, D. R. de, Palace-Berl, F., et al. (2023). Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial. Frontiers in Endocrinology, 13( ja 2023), 1089938. doi:10.3389/fendo.2022.1089938NLM
Nehmi Filho V, Santamarina AB, Freitas JA de, Trarbach EB, Oliveira DR de, Palace-Berl F, Souza E de, Miranda DA de, Garcia AE, Otoch JP, Pessoa AFM. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial [Internet]. Frontiers in Endocrinology. 2023 ; 13( ja 2023): 1089938.[citado 2024 maio 10 ] Available from: https://doi.org/10.3389/fendo.2022.1089938Vancouver
Nehmi Filho V, Santamarina AB, Freitas JA de, Trarbach EB, Oliveira DR de, Palace-Berl F, Souza E de, Miranda DA de, Garcia AE, Otoch JP, Pessoa AFM. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial [Internet]. Frontiers in Endocrinology. 2023 ; 13( ja 2023): 1089938.[citado 2024 maio 10 ] Available from: https://doi.org/10.3389/fendo.2022.1089938
